BACKGROUND: It has been proposed that elements of the renin angiotensin system expressed in the arterial wall are critical for the development of atherosclerosis. Angiotensin converting enzyme (ACE) is highly expressed by the endothelium and is responsible for a critical enzymatic step in the generation of angiotensin II. However, the functional contribution of ACE expression in the vascular wall in atherogenesis is unknown. Therefore, we made use of unique genetic models in which mice without the expression of ACE in the vascular wall were crossed with ApoE(-/-) mice in order to determine the contribution of tissue ACE expression to atherosclerotic lesion formation. METHODS AND RESULTS: Mice expressing either a soluble form of ACE (ACE 2/2) or mice with somatic ACE expression restricted to the liver and kidney (ACE 3/3) on an ApoE(-/-) background were placed on a standard chow or Western diet for 6 months. Atherosclerotic lesion area in the ACE 2/2 mice was significantly lower than that seen in the ACE 3/3 mice. However, these animals also had significantly lower blood pressure and reduced plasma ACE activity which precluded establishing a specific causal relationship between absent tissue ACE activity and decreased atherosclerotic lesion extent. Therefore, we studied the ACE 3/3 mice which are normotensive and lack vascular ACE expression. In the ACE 3/3 animals, atherosclerotic lesion area was not different from wild type controls despite reduced plasma ACE activity. CONCLUSIONS: We concluded that under these experimental conditions, expression of ACE in the arterial wall is not required for atherosclerotic lesion formation. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
BACKGROUND: It has been proposed that elements of the renin angiotensin system expressed in the arterial wall are critical for the development of atherosclerosis. Angiotensin converting enzyme (ACE) is highly expressed by the endothelium and is responsible for a critical enzymatic step in the generation of angiotensin II. However, the functional contribution of ACE expression in the vascular wall in atherogenesis is unknown. Therefore, we made use of unique genetic models in which mice without the expression of ACE in the vascular wall were crossed with ApoE(-/-) mice in order to determine the contribution of tissue ACE expression to atherosclerotic lesion formation. METHODS AND RESULTS:Mice expressing either a soluble form of ACE (ACE 2/2) or mice with somatic ACE expression restricted to the liver and kidney (ACE 3/3) on an ApoE(-/-) background were placed on a standard chow or Western diet for 6 months. Atherosclerotic lesion area in the ACE 2/2mice was significantly lower than that seen in the ACE 3/3mice. However, these animals also had significantly lower blood pressure and reduced plasma ACE activity which precluded establishing a specific causal relationship between absent tissue ACE activity and decreased atherosclerotic lesion extent. Therefore, we studied the ACE 3/3mice which are normotensive and lack vascular ACE expression. In the ACE 3/3 animals, atherosclerotic lesion area was not different from wild type controls despite reduced plasma ACE activity. CONCLUSIONS: We concluded that under these experimental conditions, expression of ACE in the arterial wall is not required for atherosclerotic lesion formation. Copyright 2009 Elsevier Ireland Ltd. All rights reserved.
Authors: V J Dzau; K Bernstein; D Celermajer; J Cohen; B Dahlöf; J Deanfield; J Diez; H Drexler; R Ferrari; W van Gilst; L Hansson; B Hornig; A Husain; C Johnston; H Lazar; E Lonn; T Lüscher; J Mancini; A Mimran; C Pepine; T Rabelink; W Remme; L Ruilope; M Ruzicka; H Schunkert; K Swedberg; T Unger; D Vaughan; M Weber Journal: Am J Cardiol Date: 2001-11-08 Impact factor: 2.778
Authors: Justin Cole; Du Le Quach; Karthik Sundaram; Pierre Corvol; Mario R Capecchi; Kenneth E Bernstein Journal: Circ Res Date: 2002-01-11 Impact factor: 17.367
Authors: Y P Sun; B Q Zhu; A E Browne; S Pulukurthy; T M Chou; K Sudhir; S A Glantz; P C Deedwania; K Chatterjee; W W Parmley Journal: J Cardiovasc Pharmacol Ther Date: 2001-04 Impact factor: 2.457
Authors: Riccardo Candido; Karin A Jandeleit-Dahm; Zemin Cao; Stefan P Nesteroff; Wendy C Burns; Stephen M Twigg; Rodney J Dilley; Mark E Cooper; Terri J Allen Journal: Circulation Date: 2002-07-09 Impact factor: 29.690
Authors: Victor J Dzau; Kenneth Bernstein; David Celermajer; Jerome Cohen; Björn Dahlöf; John Deanfield; Javier Diez; Helmut Drexler; Roberto Ferrari; Wiek Van Gilst; Lennart Hansson; Burkhard Hornig; Ahsan Husain; Colin Johnston; Harold Lazar; Eva Lonn; Thomas Lüscher; John Mancini; Albert Mimran; Carl Pepine; Ton Rabelink; Willem Remme; Luis Ruilope; Marcel Ruzicka; Heribert Schunkert; Karl Swedberg; Thomas Unger; Douglas Vaughan; Michael Weber Journal: Cardiovasc Drugs Ther Date: 2002-03 Impact factor: 3.727
Authors: Xiaofeng Chen; Deborah A Howatt; Anju Balakrishnan; Jessica J Moorleghen; Congqing Wu; Lisa A Cassis; Alan Daugherty; Hong Lu Journal: Arterioscler Thromb Vasc Biol Date: 2016-04-07 Impact factor: 8.311
Authors: Sean E Thatcher; Xuan Zhang; Deborah A Howatt; Hong Lu; Susan B Gurley; Alan Daugherty; Lisa A Cassis Journal: Arterioscler Thromb Vasc Biol Date: 2011-01-20 Impact factor: 8.311